Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

application of m6A modification related combined genome in predicting curative effect of immunotherapy for patients with renal clear cell carcinoma

A technology for renal clear cell carcinoma and immunotherapy, which is applied in the field of medical biological detection, can solve the problems of decreased expression and the ability to stimulate T cell activation, etc., and achieve the effect of improving the survival rate

Active Publication Date: 2021-10-01
FUDAN UNIV SHANGHAI CANCER CENT
View PDF5 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Decreased expression of co-stimulatory molecules CD80 and CD40 by METTL3-specific depletion reduces ability to stimulate T cell activation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • application of m6A modification related combined genome in predicting curative effect of immunotherapy for patients with renal clear cell carcinoma
  • application of m6A modification related combined genome in predicting curative effect of immunotherapy for patients with renal clear cell carcinoma
  • application of m6A modification related combined genome in predicting curative effect of immunotherapy for patients with renal clear cell carcinoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Example 1: Construction of Immunotherapy Predictive Score

[0041] One, m 6 Identification of a transcriptional regulatory subtype

[0042] The RNA-seq data of 602 clear cell renal cell carcinoma tumors and adjacent normal tissues (72 adjacent normal tissues and 530 tumor tissues) were downloaded from The Cancer Genome Atlas (TCGA). Applicants then extracted 21 m from RNA-seq 6 A expression data of regulatory factors, including 8 writers (METTL3, RBM15, METTL14, RBM15B, KIAA1429, WTAP, CBLL1, ZC3H13), 2 erasers (FTO, ALKBH5) and 11 readers (YTHDF1, YTHDF2, YTHDF3, YTHDC1, YTHDC2, HNRNPC, IGF2BP1, HNRNPA2B1, LRPPRC, FMR1, ELAVL1).

[0043] m 6 Differences in the expression of A regulators, 21 m in tumor tissues and adjacent normal tissues 6 There are differences in the expression of A regulators, the vast majority of m 6 There is a significant difference in the distribution of A regulatory factors in tumor tissues and adjacent normal tissues ( figure 1 A); while e...

Embodiment 2

[0053] Example 2 External Verification

[0054] From June 20018 to September 2020, 98 surgical specimens of ccRCC patients who had received immune checkpoint inhibitor therapy were selected from the Urology Department of Shanghai Cancer Center, Fudan University. Tissue samples including ccRCC and normal tissues were collected during surgery and are available from the FUSCC tissue bank.

[0055] 1. Real-time quantitative PCR (RT-qPCR) analysis

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medical biological detection, provides a new application of a combined genome of HNRNPA2B1 and ALKBH5, and particularly relates to an application in preparation of a reagent or a kit for predicting the curative effect of renal clear cell carcinoma immunotherapy. The invention also provides a renal clear cell carcinoma immunotherapy curative effect prediction kit and a renal clear cell carcinoma immunotherapy curative effect prediction system. The gene combination is derived from a renal clear cell carcinoma m6A modification mode differential expression mode, discovery of the m6A modification related gene combination model provides a brand-new strategy for predicting the immune treatment effect of a renal clear cell carcinoma patient, clinical doctors can be guided to implement an individualized precise treatment strategy, the survival rate of the patient is increased, and the method has important guiding significance for immunotherapy application of patients with renal clear cell carcinoma.

Description

technical field [0001] The invention belongs to the technical field of medical biological detection, and relates to the m 6 The use of A modification-related combined genome as a marker is specifically the application of the combined genome in the preparation of a kit for predicting the curative effect of renal clear cell carcinoma immunotherapy and a prediction system. Background technique [0002] Renal cell carcinoma is one of the most common malignancies of the genitourinary system, accounting for about 5% of all adult males and 3% of females. According to statistics, in 2019, there were about 73,820 new cases of kidney cancer and 14,770 deaths in the United States. There are about 66,800 new kidney cancer patients in my country every year, ranking second in the incidence of urinary system tumors. Clear cell renal cell carcinoma (ccRCC) is the most common pathological type of renal cancer with a high degree of malignancy, accounting for about 70-85% of all renal cancer ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886C12N15/11G16B50/00G16B35/00
CPCC12Q1/6886G16B50/00G16B35/00C12Q2600/158C12Q2600/154
Inventor 田熙瞿元元徐文浩艾合太木江·安外尔朱殊璇王骏施国海叶定伟
Owner FUDAN UNIV SHANGHAI CANCER CENT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com